Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Understanding the human estrogen receptor-alpha using targeted mutagenesis.

Debra F Skafar1, Shohei Koide

  • 1Department of Physiology, Wayne State University School of Medicine, 540 E. Canfield, Detroit, MI 48201, USA. dskafar@med.wayne.edu

Molecular and Cellular Endocrinology
|January 31, 2006
PubMed
Summary

The estrogen receptor-alpha (ERalpha) F domain and helix 12 interactions are crucial for its activity. Mutations reveal how these regions modulate responses to estradiol and tamoxifen, impacting breast cancer treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Promiscuous RNA binding by WDR5 remodels the KMT2A (MLL1) histone methyltransferase complex to an inactive state.

bioRxiv : the preprint server for biology·2026
Same author

Protein Engineering-Enabled Cryo-EM Investigation of Small GTPases.

Journal of molecular biology·2026
Same author

TagC-RED: An Infrared-Triggered Retro-Ene Reaction for Deep-Tissue Bioconjugation.

Journal of the American Chemical Society·2026
Same author

LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer.

Cancer discovery·2026
Same author

The integrated stress response promotes immune evasion through lipocalin 2.

Nature·2026
Same author

Engineered antibodies that stabilize drug-modified KRAS<sup>G12C</sup> neoantigens enable selective and potent cross-HLA immunotherapy.

Nature communications·2025

Area of Science:

  • Molecular Biology
  • Endocrinology
  • Cancer Research

Background:

  • Estrogen receptor-alpha (ERalpha) is vital in normal physiology and breast cancer.
  • ERalpha is a key target for anti-cancer therapies.
  • Understanding ERalpha's ligand-regulated activity is crucial for drug development.

Purpose of the Study:

  • To investigate the role of the F domain in ERalpha's ligand-stimulated activity.
  • To explore the function of hydrophobic and hydrogen-bonding interactions at the start of helix 12.
  • To identify specific regions and interactions critical for ERalpha's activity using structure-based hypotheses.

Main Methods:

  • Site-directed mutagenesis guided by protein structures and secondary structure predictions.
  • Construction and functional testing of ERalpha mutants within the F domain and helix 12.

Related Experiment Videos

  • Analysis of receptor response to estradiol (E2) and 4-hydroxytamoxifen (4-OHT), including binding affinity and cooperative interactions.

    • Main Results:

    • Mutations in the F domain alter ERalpha's response to E2 and 4-OHT, affecting agonist and antagonist activities.
    • F domain deletion increases E2 affinity, while proline mutation alters binding cooperativity.
    • Mutating Leucine-536 (L536) impacts ERalpha's response to ligands and alters its conformation, coupling ligand binding to receptor structure.

    Conclusions:

    • The ERalpha F domain exhibits significant functional complexity and modulates receptor activity.
    • Specific interactions at the start of helix 12, like L536, are critical for coupling ligand binding to conformational changes.
    • Structure-guided functional studies effectively identify key regions and interactions governing ERalpha's ligand-stimulated activity.